COGNITION THERAPEUTICS INC (CGTX) Stock Price & Overview
NASDAQ:CGTX • US19243B1026
Current stock price
The current stock price of CGTX is 0.8914 USD. Today CGTX is up by 17.37%. In the past month the price decreased by -15.91%. In the past year, price increased by 151.67%.
CGTX Key Statistics
- Market Cap
- 78.684M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.33
- Dividend Yield
- N/A
CGTX Stock Performance
CGTX Stock Chart
CGTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CGTX. When comparing the yearly performance of all stocks, CGTX is one of the better performing stocks in the market, outperforming 90.63% of all stocks.
CGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CGTX. The financial health of CGTX is average, but there are quite some concerns on its profitability.
CGTX Earnings
CGTX Forecast & Estimates
10 analysts have analysed CGTX and the average price target is 3.57 USD. This implies a price increase of 300.49% is expected in the next year compared to the current price of 0.8914.
CGTX Groups
Sector & Classification
CGTX Financial Highlights
Over the last trailing twelve months CGTX reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS increased by 62.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.54% | ||
| ROE | -68.53% | ||
| Debt/Equity | 0 |
CGTX Ownership
CGTX Latest News, Press Relases and Analysis
CGTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.31 | 900.456B | ||
| JNJ | JOHNSON & JOHNSON | 20.96 | 587.99B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.764B | ||
| PFE | PFIZER INC | 9.56 | 162.403B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.75 | 125.711B | ||
| ZTS | ZOETIS INC | 16.57 | 49.512B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 27.972B | ||
| VTRS | VIATRIS INC | 5.43 | 15.693B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.98 | 11.495B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.787B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.274B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.606B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.81 | 4.465B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CGTX
Company Profile
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company is headquartered in Purchase, New York and currently employs 25 full-time employees. The company went IPO on 2021-10-08. The firm is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. The company is developing other product candidates in the area of synucleinopathies.
Company Info
IPO: 2021-10-08
COGNITION THERAPEUTICS INC
2500 Westchester Ave
Purchase NEW YORK US
Employees: 25
Phone: 13026974590
COGNITION THERAPEUTICS INC / CGTX FAQ
What does CGTX do?
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company is headquartered in Purchase, New York and currently employs 25 full-time employees. The company went IPO on 2021-10-08. The firm is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. The company is developing other product candidates in the area of synucleinopathies.
Can you provide the latest stock price for COGNITION THERAPEUTICS INC?
The current stock price of CGTX is 0.8914 USD. The price increased by 17.37% in the last trading session.
Does CGTX stock pay dividends?
CGTX does not pay a dividend.
How is the ChartMill rating for COGNITION THERAPEUTICS INC?
CGTX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is COGNITION THERAPEUTICS INC (CGTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CGTX.
Can you provide the number of employees for COGNITION THERAPEUTICS INC?
COGNITION THERAPEUTICS INC (CGTX) currently has 25 employees.
What is the Short Interest ratio of COGNITION THERAPEUTICS INC (CGTX) stock?
The outstanding short interest for COGNITION THERAPEUTICS INC (CGTX) is 8.12% of its float.